Last reviewed · How we verify

Ondansetron 8mg

Ain Shams University · FDA-approved active Small molecule Quality 5/100

Ondansetron 8mg is a Small molecule drug developed by Ain Shams University. It is currently FDA-approved. Also known as: Higher dose Ondanseteron group, Placebo- 4ml of 0.9% IV saline, high ondansetron, Zofran.

Ondansetron 8mg, developed by Ain Shams University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and patent protection, which helps maintain its competitive edge. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameOndansetron 8mg
Also known asHigher dose Ondanseteron group, Placebo- 4ml of 0.9% IV saline, high ondansetron, Zofran, OND
SponsorAin Shams University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ondansetron 8mg

What is Ondansetron 8mg?

Ondansetron 8mg is a Small molecule drug developed by Ain Shams University.

Who makes Ondansetron 8mg?

Ondansetron 8mg is developed and marketed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

Is Ondansetron 8mg also known as anything else?

Ondansetron 8mg is also known as Higher dose Ondanseteron group, Placebo- 4ml of 0.9% IV saline, high ondansetron, Zofran, OND.

What development phase is Ondansetron 8mg in?

Ondansetron 8mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing